Strategic Acquisition Growth The recent acquisition of Renaissance Lakewood by LTS Lohmann Therapie-Systeme AG indicates a strategic expansion, providing opportunities to collaborate on larger projects and integrate innovative nasal spray and injectable development capabilities into your portfolio.

Specialized Nasal Expertise Renaissance possesses over 20 years of experience in nasal spray development and manufacturing, making it an ideal partner for companies seeking specialized formulation and production services for nasal drug delivery systems.

Collaborative Research Projects Renaissance’s active partnerships with biotech firms like Tiziana Life Sciences and St. Jude Children’s Research Hospital highlight its role as a trusted development partner, opening avenues for joint development of novel therapies targeting pediatric and immunomodulation indications.

Robust Industry Position With a revenue range of $100M to $250M and a workforce of up to 1,000 employees, Renaissance is positioned as a competitive player in the pharmaceutical CDMO sector, especially in sterile injectables and nasal spray manufacturing, appealing to bioscience firms seeking reliable manufacturing partners.

Technological and Regulatory Capabilities Utilizing advanced tech stacks like Google Analytics, SCADA, and Google Cloud, combined with its expertise in handling DEA Schedule I-V substances, Renaissance offers comprehensive compliance and quality assurance that can support clients in navigating complex regulatory environments.